Search

Your search keyword '"Straube, Richard"' showing total 118 results
Start Over Author "Straube, Richard"
118 results on '"Straube, Richard"'

1. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis

Author

Achleitner, Martin, Steenblock, Charlotte, Dänhardt, Juliane, Jarzebska, Natalia, Kardashi, Romina, Kanczkowski, Waldemar, Straube, Richard, Rodionov, Roman N., Bornstein, Nitzan, Tselmin, Sergey, Kaiser, Frank, Bucher, Ronald, Barbir, Mahmoud, Wong, Ma-Li, Voit-Bak, Karin, Licinio, Julio, and Bornstein, Stefan R.

Published
2023
Full Text
View/download PDF

7. HyBryte™ use in early-stage cutaneous T-cell lymphoma

Author

Poligone, Brian, primary, Alexander-Savino, Carolina V., additional, Kim, Ellen J., additional, Mangold, Aaron R., additional, Desimone, Jennifer, additional, Wong, Henry K., additional, Rumage, Adam T., additional, Donini, Oreola, additional, Haulenbeek, Andrea, additional, Schaber, Christopher J., additional, Straube, Richard, additional, Pullion, Christopher, additional, and Rook, Alain H., additional

Published
2023
Full Text
View/download PDF

8. Post COVID and Apheresis – Where are we Standing?

Author

Steenblock, Charlotte, Walther, Romy, Tselmin, Sergey, Jarzebska, Natalia, Voit-Bak, Karin, Toepfner, Nicole, Siepmann, Timo, Passauer, Jens, Hugo, Christian, Wintermann, Gloria, Julius, Ulrich, Barbir, Mahmoud, Khan, Tina Z, Puhan, Milo A, Straube, Richard, Hohenstein, Bernd, Bornstein, Stefan R, Rodionov, Roman N, University of Zurich, and Steenblock, Charlotte

Subjects
1303 Biochemistry, SARS-CoV-2, Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, 10265 Clinic for Endocrinology and Diabetology, COVID-19, 610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), General Medicine, 1308 Clinical Biochemistry, 2704 Biochemistry (medical), Biochemistry, 1310 Endocrinology, 2712 Endocrinology, Diabetes and Metabolism, Post-Acute COVID-19 Syndrome, Endocrinology, Germany, Blood Component Removal, Humans
Abstract

A continual increase in cases of Long/Post COVID constitutes a medical and socioeconomic challenge to health systems around the globe. While the true extent of this problem cannot yet be fully evaluated, recent data suggest that up to 20% of people with confirmed SARS-CoV-2 suffer from clinically relevant symptoms of Long/Post COVID several weeks to months after the acute phase. The clinical presentation is highly variable with the main symptoms being chronic fatigue, dyspnea, and cognitive symptoms. Extracorporeal apheresis has been suggested to alleviate symptoms of Post/COVID. Thus, numerous patients are currently treated with apheresis. However, at present there is no data from randomized controlled trials available to confirm the efficacy. Therefore, physicians rely on the experience of practitioners and centers performing this treatment. Here, we summarize clinical experience on extracorporeal apheresis in patients with Post/COVID from centers across Germany.

Published
2022
Full Text
View/download PDF

11. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis

Author

Achleitner, Martin; https://orcid.org/0000-0003-3224-6219, Steenblock, Charlotte; https://orcid.org/0000-0002-9635-4860, Dänhardt, Juliane, Jarzebska, Natalia; https://orcid.org/0000-0002-1275-2942, Kardashi, Romina; https://orcid.org/0009-0001-2818-1128, Kanczkowski, Waldemar; https://orcid.org/0000-0002-5595-8393, Straube, Richard, Rodionov, Roman N; https://orcid.org/0000-0002-7470-7776, Bornstein, Nitzan, Tselmin, Sergey, Kaiser, Frank, Bucher, Ronald, Barbir, Mahmoud, Wong, Ma-Li; https://orcid.org/0000-0003-1512-3073, Voit-Bak, Karin, Licinio, Julio; https://orcid.org/0000-0001-6905-5884, Bornstein, Stefan R; https://orcid.org/0000-0002-5211-2536, Achleitner, Martin; https://orcid.org/0000-0003-3224-6219, Steenblock, Charlotte; https://orcid.org/0000-0002-9635-4860, Dänhardt, Juliane, Jarzebska, Natalia; https://orcid.org/0000-0002-1275-2942, Kardashi, Romina; https://orcid.org/0009-0001-2818-1128, Kanczkowski, Waldemar; https://orcid.org/0000-0002-5595-8393, Straube, Richard, Rodionov, Roman N; https://orcid.org/0000-0002-7470-7776, Bornstein, Nitzan, Tselmin, Sergey, Kaiser, Frank, Bucher, Ronald, Barbir, Mahmoud, Wong, Ma-Li; https://orcid.org/0000-0003-1512-3073, Voit-Bak, Karin, Licinio, Julio; https://orcid.org/0000-0001-6905-5884, and Bornstein, Stefan R; https://orcid.org/0000-0002-5211-2536

Abstract

In the aftermath of the COVID-19 pandemic, we are witnessing an unprecedented wave of post-infectious complications. Most prominently, millions of patients with Long-Covid complain about chronic fatigue and severe post-exertional malaise. Therapeutic apheresis has been suggested as an efficient treatment option for alleviating and mitigating symptoms in this desperate group of patients. However, little is known about the mechanisms and biomarkers correlating with treatment outcomes. Here, we have analyzed in different cohorts of Long-Covid patients specific biomarkers before and after therapeutic apheresis. In patients that reported a significant improvement following two cycles of therapeutic apheresis, there was a significant reduction in neurotransmitter autoantibodies, lipids, and inflammatory markers. Furthermore, we observed a 70% reduction in fibrinogen, and following apheresis, erythrocyte rouleaux formation and fibrin fibers largely disappeared as demonstrated by dark field microscopy. This is the first study demonstrating a pattern of specific biomarkers with clinical symptoms in this patient group. It may therefore form the basis for a more objective monitoring and a clinical score for the treatment of Long-Covid and other postinfectious syndromes.

Published
2023

12. Precision medicine approach for cardiometabolic risk factors in therapeutic apheresis

Author

Yin, Xiaoke, primary, Takov, Kaloyan, additional, Straube, Richard, additional, Voit-Bak, Karin, additional, Gräßler, Jürgen, additional, Julius, Ulrich, additional, Tselmin, Sergey, additional, Rodionov, Roman, additional, Barbir, Mahmoud, additional, Walls, Matthew, additional, Theofilatos, Konstantinos, additional, Mayr, Manuel, additional, and Bornstein, Stefan, additional

Published
2022
Full Text
View/download PDF

13. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Author

Kim, Ellen J., primary, Mangold, Aaron R., additional, DeSimone, Jennifer A., additional, Wong, Henry K., additional, Seminario-Vidal, Lucia, additional, Guitart, Joan, additional, Appel, James, additional, Geskin, Larisa, additional, Lain, Edward, additional, Korman, Neil J., additional, Zeitouni, Nathalie, additional, Nikbakht, Neda, additional, Dawes, Kenneth, additional, Akilov, Oleg, additional, Carter, Joi, additional, Shinohara, Michi, additional, Kuzel, Timothy M., additional, Piette, Warren, additional, Bhatia, Neal, additional, Musiek, Amy, additional, Pariser, David, additional, Kim, Youn H., additional, Elston, Dirk, additional, Boh, Erin, additional, Duvic, Madeleine, additional, Huen, Auris, additional, Pacheco, Theresa, additional, Zwerner, Jeffrey P., additional, Lee, Seung Tae, additional, Girardi, Michael, additional, Querfeld, Christiane, additional, Bohjanen, Kimberly, additional, Olsen, Elise, additional, Wood, Gary S., additional, Rumage, Adam, additional, Donini, Oreola, additional, Haulenbeek, Andrea, additional, Schaber, Christopher J., additional, Straube, Richard, additional, Pullion, Christopher, additional, Rook, Alain H., additional, and Poligone, Brian, additional

Published
2022
Full Text
View/download PDF

14. Adressen

Author

Schmiedel, Volker, primary, Augustin, Matthias, additional, Altner, Nils, additional, Berz, Reinhold, additional, Bischof, Stefan, additional, Bischoff, Hans Peter, additional, Brenke, Rainer, additional, Chopra, Ananda Samir, additional, Donate, Hans-Peter, additional, Feldhaus, Simon, additional, Grombach, Heinz, additional, Nicola Gruber, H.P., additional, Inderst, Rudolf, additional, Jansen, Natalie, additional, Jütte, Robert, additional, Kammerer, Susanne, additional, Köhler, Bodo, additional, Harald Krebs, H.P., additional, Krug, Marianne, additional, Langhorst, Jost, additional, Leitzmann, Claus, additional, Lachtermann, Ella, additional, Lehle, Götz, additional, Marquardt, Hanne, additional, Milz, Franz, additional, Paul, Anna, additional, Petri, Ulrich, additional, Rohde, Jürgen, additional, Rüffer, Andreas, additional, Sauer, Helmut, additional, Scheffer, Mechthild, additional, Schmiedel, Volker, additional, Schwan, Uwe, additional, Straube, Richard, additional, Tempelhof, Siegbert, additional, Völkel, Ursula, additional, Meyer, Frank, additional, Weber, Klaus, additional, Weingart, Johannes, additional, Wenigmann, Margret, additional, and Wiesendanger, Konrad, additional

Published
2017
Full Text
View/download PDF

15. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?

Author

Bornstein, Stefan R; https://orcid.org/0000-0002-5211-2536, Voit-Bak, Karin, Donate, Timo, Rodionov, Roman N, Gainetdinov, Raul R, Tselmin, Sergey, Kanczkowski, Waldemar, Müller, Gregor M, Achleitner, Martin, Wang, Jun, Licinio, Julio; https://orcid.org/0000-0001-6905-5884, Bauer, Michael, Young, Allan H; https://orcid.org/0000-0003-2291-6952, Thuret, Sandrine; https://orcid.org/0000-0003-1260-8083, Bechmann, Nicole, Straube, Richard, Bornstein, Stefan R; https://orcid.org/0000-0002-5211-2536, Voit-Bak, Karin, Donate, Timo, Rodionov, Roman N, Gainetdinov, Raul R, Tselmin, Sergey, Kanczkowski, Waldemar, Müller, Gregor M, Achleitner, Martin, Wang, Jun, Licinio, Julio; https://orcid.org/0000-0001-6905-5884, Bauer, Michael, Young, Allan H; https://orcid.org/0000-0003-2291-6952, Thuret, Sandrine; https://orcid.org/0000-0003-1260-8083, Bechmann, Nicole, and Straube, Richard

Abstract

As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing breathlessness and fatigue even months after the onset of the disease. This overwhelming phenomenon has not been well defined and has been called "post-COVID syndrome" or "long-COVID" [1]. There are striking similarities to myalgic encephalomyelitis also called chronic fatigue syndrome linked to a viral and autoimmune pathogenesis. In both disorders neurotransmitter receptor antibodies against ß-adrenergic and muscarinic receptors may play a key role. We found similar elevation of these autoantibodies in both patient groups. Extracorporeal apheresis using a special filter seems to be effective in reducing these antibodies in a significant way clearly improving the debilitating symptoms of patients with chronic fatigue syndrome. Therefore, such a form of neuropheresis may provide a promising therapeutic option for patients with post-COVID-19 syndrome. This method will also be effective when other hitherto unknown antibodies and inflammatory mediators are involved.

Published
2022

17. Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

Author

Straube, Richard, Müller, Gregor, Voit-Bak, Karin, Tselmin, Sergey, Julius, Ulrich, Schatz, Ulrike, Rietzsch, Hannes, Reichmann, Heinz, Chrousos, George P, Schürmann, Annette, Jarc, Luka, Ziemssen, Tjalf, Siepmann, Timo, Bornstein, Stefan R, University of Zurich, and Straube, Richard

Subjects
2712 Endocrinology, Diabetes and Metabolism, 1303 Biochemistry, 10265 Clinic for Endocrinology and Diabetology, 610 Medicine & health, 1308 Clinical Biochemistry, 2704 Biochemistry (medical), 1310 Endocrinology
Published
2019

18. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?

Author

Bornstein, Stefan R., primary, Voit-Bak, Karin, additional, Donate, Timo, additional, Rodionov, Roman N., additional, Gainetdinov, Raul R., additional, Tselmin, Sergey, additional, Kanczkowski, Waldemar, additional, Müller, Gregor M., additional, Achleitner, Martin, additional, Wang, Jun, additional, Licinio, Julio, additional, Bauer, Michael, additional, Young, Allan H., additional, Thuret, Sandrine, additional, Bechmann, Nicole, additional, and Straube, Richard, additional

Published
2021
Full Text
View/download PDF

19. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial

Author

Taylor, Robert W., Zimmerman, Janice L., Dellinger, R. Phillip, Straube, Richard C., Criner, Gerard J., Davis, Kenneth Jr., Kelly, Kathleen M., Smith, Thomas C., and Small, Robert J.

Subjects
Nitrogen oxide -- Health aspects, Nitrogen oxide -- Research, Lung diseases -- Care and treatment, Lung diseases -- Research, Nitric oxide -- Health aspects, Nitric oxide -- Research
Abstract

The clinical efficacy of low-dose (5-ppm) inhaled nitric oxide in patients with acute lung injury is evaluated. Inhaled nitric oxide at a dose of 5 ppm in patients with acute lung injury not due to sepsis and without evidence of nonpulumonary organ system dysfunction results in short-term oxygenation improvements, but has no substantial impact on the duration of ventilatory support or mortality.

Published
2004

20. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study

Author

Davidson, Dennis, Barefield, Elaine S., Kattwinkel, John, Dudell, Golde, Damask, Michael, Straube, Richard, Rhines, Jared, and Chang, Cheng-Tao

Subjects
Care and treatment, Evaluation, Health aspects, Persistent fetal circulation syndrome -- Care and treatment, Newborn infants -- Evaluation -- Care and treatment, Nitric oxide -- Health aspects -- Evaluation, Respiratory therapy -- Evaluation -- Health aspects, Respiratory therapy for newborn infants -- Evaluation -- Care and treatment, Infants (Newborn) -- Evaluation -- Care and treatment
Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of acute respiratory failure, characterized by systemic hypoxemia associated with extrapulmonary shunting of venous blood and evidence of elevated levels [...]

Published
1998

23. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial

Author

Ziegler, Elizabeth J., Fisher, Charles J., Jr., Sprung, Charles L., Straube, Richard C., Sadoff, Jerald C., Foulke, Garrett E., Wortel, Cornelis H., Fink, Mitchell P., Dellinger, R. Phillip, Teng, Nelson N.H., Allen, I. Elaine, Berger, Harvey J., Knatterud, Genell L., LoBuglio, Albert F., and Smith, Craig R.

Subjects
Bacteremia -- Care and treatment, Gram-negative bacterial infections -- Care and treatment, Gram-negative bacteria -- Physiological aspects, Septic shock -- Care and treatment
Abstract

Septicemia, in which bacteria have spread from an infection and are being carried through the body in the blood, is a major cause of illness and death, particularly among hospitalized patients. About 400,000 cases occur in the US each year and the incidence is on the rise. About 30 percent of these cases involve gram-negative bacteria; the mortality for gram-negative bacteremia ranges from 20 to 60 percent, depending on the characteristics of the patients involved. A significant portion of the physiological damage that results from gram-negative septicemia stems from the poisonous effects of endotoxins. Endotoxins are a class of lipopolysaccharide compounds, and the different endotoxin molecules share a common feature, called lipid A, which is believed to be directly responsible for the toxic effects. It is possible to obtain antibodies to the region of endotoxin containing the lipid A by inoculating human volunteers, but there are numerous drawbacks to this approach. Now, however, a line of hybrid human cells has been developed which secretes a monoclonal antibody directed against the endotoxins. This antibody, dubbed HA-1A, has been tested in a controlled study of 543 patients with bacterial sepsis. Among the 343 patients whose septicemia was found not to involve gram-negative bacteria, intravenous administration of the antibody provided no benefit, as might be expected. However, among the patients with gram-negative bacteremia, there were 32 deaths among 105 patients injected with HA-1A, in contrast to 45 deaths among the 92 patients treated only with placebo. When only the patients who entered bacteremic shock were considered, 18 of 54 antibody recipients died, compared with 27 of 47 recipients of placebo. The study demonstrated that the human monoclonal antibody HA-1A is effective in the treatment of sepsis with gram-negative bacteria. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

25. Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

Author

Straube, Richard, additional, Müller, Gregor, additional, Voit-Bak, Karin, additional, Tselmin, Sergey, additional, Julius, Ulrich, additional, Schatz, Ulrike, additional, Rietzsch, Hannes, additional, Reichmann, Heinz, additional, Chrousos, George P., additional, Schürmann, Annette, additional, Jarc, Luka, additional, Ziemssen, Tjalf, additional, Siepmann, Timo, additional, and Bornstein, Stefan R., additional

Published
2019
Full Text
View/download PDF

26. Extracorporeal apheresis therapy for Alzheimer disease—targeting lipids, stress, and inflammation

Author

Bornstein, Stefan R., primary, Voit-Bak, Karin, additional, Rosenthal, Peter, additional, Tselmin, Sergey, additional, Julius, Ulrich, additional, Schatz, Ulrike, additional, Boehm, Bernhard O., additional, Thuret, Sandrine, additional, Kempermann, Gerd, additional, Reichmann, Heinz, additional, Chrousos, George P., additional, Licinio, Julio, additional, Wong, Ma-Li, additional, Schally, Andrew V., additional, and Straube, Richard, additional

Published
2019
Full Text
View/download PDF

28. Lipid Profiles in Lyme Borreliosis: A Potential Role for Apheresis?

Author

Straube, Richard, additional, Voit-Bak, Karin, additional, Gor, A., additional, Steinmeier, Til, additional, Chrousos, George P., additional, Boehm, Bernhard Otto, additional, Birkenfeld, Andreas L., additional, Barbir, Mahmoud, additional, Balanzew, Wladimir, additional, and Bornstein, Stefan R., additional

Published
2019
Full Text
View/download PDF

35. Rheopheresis as therapeutic option in patients with recurring sudden sensorineural hearing loss refractory to standard therapy

Author

Uygun-Kiehne, Selma, Straube, Richard, Heibges, Andreas, Klingel, Reinhard, and Davids, Heino

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background and objective: For patients suffering from recurring sudden hearing loss (SHL) refractory to standard infusion therapy, new therapeutic options have to be established. LDL-fibrinogen apheresis, covering Rheopheresis and HELP-apheresis for the indication of SHL, has been shown to be equally[for full text, please go to the a.m. URL], 80th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

Published
2009
Full Text
View/download PDF

37. Inhaled Nitric Oxide

Author

Dellinger, R. Phillip, primary, Zimmerman, Janice, additional, Taylor, Robert W., additional, and Straube, Richard C., additional

Published
1999
Full Text
View/download PDF

38. Nitric Oxide

Author

Dellinger, R. Phillip, primary, Zimmerman, Janice L., additional, Taylor, Robert W., additional, and Straube, Richard C., additional

Published
1999
Full Text
View/download PDF

44. Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome

Author

Romano, Michael J., primary, Kearns, Gregory L., additional, Kaplan, Sheldon L., additional, Jacobs, Richard F., additional, Killian, Anthony, additional, Bradley, John S., additional, Moss, M. Michele, additional, Van Dyke, Russell, additional, Rodriguez, William, additional, and Straube, Richard C., additional

Published
1993
Full Text
View/download PDF

45. HA-1A

Author

Smith, Craig R., primary, Straube, Richard C., additional, and Ziegler, Elizabeth J., additional

Published
1992
Full Text
View/download PDF

47. The AIDS Epidemic: Dilemmas Facing Nurse Managers.

Author

Jackson, Marguerite M., Healy, Sonya A., Straube, Richard C., McPherson, Diana C., and Greenawalt, Nancy C.

Subjects
AIDS, ETIOLOGY of diseases, IMMUNOLOGICAL deficiency syndromes
Abstract

In this article authors distinguish fact from myth about AIDS and describe how the University of California San Diego Medical Center has responded to the AIDS crisis. AIDS was first described in 1981 in live sexually active homosexual young men in Los Angeles, California. By the end of 1985, almost 16,000 persons in the U.S met criteria of Centers of Disease Control and Prevention (CDC) criteria for the case definition of CDC-AIDS. The etiologic agent for AIDS was first identified in 1983 by a group working at the Pasteur Institute in Paris as the lymph adenopathy-associated virus.

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results